EQS-News: Marinomed secures financing through successful capital increase

EQS-News: Marinomed Biotech AG / Key word(s): Capital Increase
   Marinomed secures financing through successful capital increase

   13.04.2026 / 17:02 CET/CEST
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Marinomed secures financing through successful capital increase

    

   Korneuburg, Austria, April 13, 2026 Marinomed Biotech AG (“Company”) has
   successfully completed the capital increase against cash contribution
   announced on March 19, 2026. Through the rights offering to existing
   shareholders (the “Rights Offering”), 33,322 new shares were subscribed
   for by exercising subscription rights. Shares not subscribed for were
   subsequently offered in a prospectus-free private placement at a
   subscription price of EUR 14 per new share. An additional 125,717 new
   shares were placed within this framework.

   A total of 159,039 new shares of the Company were thus issued as part of
   the capital increase, with final gross proceeds of approximately EUR 2.23
   million. The transaction target of gross proceeds for the Company of at
   least EUR 2 million was therefore even exceeded.

   “We are delighted with the successful capital increase. It confirms the
   strong confidence investors have in our company and secures the financial
   foundation we need to achieve our planned milestones. This financing will
   cover our anticipated liquidity requirements and strengthen our position
   in the ongoing negotiations for the marketing of our flagship products,
   Budesolv and Tacrosolv,” said Andreas Grassauer, CEO of Marinomed.

   The settlement, delivery, and trading of all new shares under the existing
   ISIN ATMARINOMED6 on the Vienna Stock Exchange is expected to take place
   on April 20, 2026, subject to registration of the capital increase in the
   Commercial Register.

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline. The Company develops innovative
   patent-protected products based on the Marinosolv® platform. The
   Marinosolv® technology improves the solubility and bioavailability of
   hardly soluble compounds and is used to develop new therapeutics for
   autoreactive immune disorders. The Company is headquartered in Korneuburg,
   Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
   further information, please visit: [1]https://www.marinomed.com.

    

   For further inquiries contact:

   Marinomed Biotech AG         
   PR: Luca Horinek
   IR.: Tobias Meister
   T: +43 2262 90300 158
   E-Mail: [2][email protected]
   E-Mail: [3][email protected]

    

   Disclaimer

   This press release contains forward-looking statements, which are based on
   current views, expectations and projections of the management of Marinomed
   Biotech AG about future events. These forward-looking statements are
   subject to risks, uncertainties and assumptions that could cause actual
   results, performance or events to differ materially from those described
   in, or expressed or implied by, such statements. The current views,
   expectations and projections of the management of Marinomed Biotech AG may
   be identified by the context of such statements or words such as
   “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
   and “target”. Forward-looking statements are only valid as of the date
   they are made and Marinomed Biotech AG does not assume any obligation to
   update, review or revise any forward-looking statements contained in this
   press release whether as a result of new information, future developments
   or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
   trademarks of Marinomed Biotech AG. These trademarks may be owned or
   licensed in select locations only.

    

    

    

    

   ══════════════════════════════════════════════════════════════════════════

   13.04.2026 CET/CEST This Corporate News was distributed by [4]EQS Group

   View original content: [5]EQS News

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      [email protected]
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
                Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
                Market)
   EQS News ID: 2307416


    
   End of News EQS News Service


   2307416  13.04.2026 CET/CEST

   https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2307416&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2307416&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   2. mailto:[email protected]
   3. mailto:[email protected]
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2307416&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9f2b17e8b218677e74a5c353bc17ef6a&application_id=2307416&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT |

print